Drug Sponsors

Cempra, Melinta merge to form commercial-stage anti-infectives company

Wednesday, August 9, 2017

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases, and Melinta Therapeutics, a privately held company focused on discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, have announced that the companies have entered into a definitive agreement under which Melinta will merge with a subsidiary of Cempra. The merger is expected to create a company committed to discovering, developing and commercializing important anti-infective therapies for patients and physicians in areas of significant unmet need.

[Read More]

Bristol-Myers Squibb to acquire IFM Therapeutics

Wednesday, August 9, 2017

Bristol-Myers Squibb and IFM Therapeutics (IFM) announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

[Read More]

Co-Diagnostics, Synbiotics launch joint venture CoSara Diagnostics in India

Tuesday, July 25, 2017

Co-Diagnostics, a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced the recent incorporation of CoSara Diagnostics, a Joint Venture for manufacturing with Synbiotics. Synbiotics is a group company of Asence, a U.S. incorporated company specializing in supplying pharmaceutical products to international markets.

[Read More]

Endo to restructure manufacturing network

Monday, July 24, 2017

Endo International announced that after completing a comprehensive review of its manufacturing network, the company will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure of the facilities is expected to take place over the next 12 to 18 months. The Huntsville location has been impacted by declining volumes of commoditized products and these restructuring actions are intended to better match manufacturing capacity to projected future demand.

[Read More]

Enterome, Nestlé launch diagnostics company Microbiome Diagnostics Partners

Tuesday, July 11, 2017

Enterome, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in multiple diseases areas, including inflammatory bowel diseases (IBD) and liver diseases.

[Read More]

O’Connor steps down as CEO of Advaxis

Friday, July 7, 2017

Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of a proprietary Lm-based antigen delivery system, has announced his resignation from the company and its board of directors.

[Read More]

Novomer relocates headquarters to Boston

Monday, July 3, 2017

Novomer, a sustainable chemicals company, has announced the relocation of its headquarters to One Bowdoin Square in Boston on July 17. The new office—designed to meet the expanded demands of the company’s growing bio-based chemicals business—will be in the heart of Boston, less than 20 miles from the current Waltham location.

[Read More]

Lion Biotechnologies changes name to Iovance Biotherapeutics

Monday, July 3, 2017

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies to Iovance Biotherapeutics. The company’s new NASDAQ ticker symbol “IOVA” will be effective at the open of the market on June 28, 2017. The former ticker symbol “LBIO” will remain effective through the market close today, June 27, 2017. The new website for Iovance Biotherapeutics is www.iovance.com.

[Read More]